Validation of the Khorana Venous Thromboembolism Risk Score in Japanese Cancer Patients

Figures

• 

  Figure 1. Study Flowchart

• 

  Figure 2. Distributions of Malignant Diseases of 30,706 Adult Patients With Cancer (A) Female patients. (B) Male patients. CNS = central nervus system; MM = malignant lymphoma; VTE = venous thromboembolism.

• 

  Figure 3. Distribution of the KRS in Enrolled Patients Black, blue, and red columns indicate low, intermediate, and high risks of Khorana risk score (KRS), respectively.

• 

  Figure 4. VTE Incidence in the Enrolled Patients According to the KRS Each column is shown in Figure 3. Abbreviations as in Figures 2 and 3.

• 

  Central Illustration. The Current Proposed Risk Categories of Venous Thromboembolism and Mortality for Asian Patients With Cancer ROC curves of the KRS for the prediction of VTE incidence (A) and all-cause mortality (B), Kaplan–Meier analysis of all-cause mortality in the follow-up period according to the KRS (C). The 0 time point on the x-axis indicates the day of enrollment. The current proposed risk categories for VTE and mortality (D). AUC = area under the curve; CI = confidence interval; KRS = Khorana risk score; ROC = receiver operating characteristic; VTE = venous thromboembolism.

• 

  Figure 5. All-Cause Mortality of the Enrolled Patients According to the KRS Each column is shown in Figure 3. Abbreviation as in Figure 3.